Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human erythropoietin for prevention of contrast-associated nephrotoxicity in high-risk patients
2007-000994-40Phase 2Active
- Sponsor
- Gregorio Marañón University General Hospital
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in contrast-induced nephropathy (CIN) comparing epoetin beta arm, epoetin alfa arm and placebo arm (3 arms). Primary endpoint: Incidence of acute renal dysfunction on day 2 after procedure. Started Nov 2007; status: active.
02
Drugs
epoetin betaepoetin alfa
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on 2007-000994-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000994-40.